Clinical trials recruiting for Melanoma
487
Recruiting trials
51
US states with sites
48
Countries
5%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nivolumab | 38 |
| Pembrolizumab | 34 |
| Ipilimumab | 21 |
| Cyclophosphamide | 14 |
| Binimetinib | 8 |
| Cemiplimab | 7 |
| Fludarabine | 7 |
| Aldesleukin | 6 |
| Encorafenib | 6 |
| Paclitaxel | 6 |
| Tebentafusp | 6 |
| Bevacizumab | 5 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 93 |
| California | 86 |
| Florida | 70 |
| New York | 70 |
| Pennsylvania | 58 |
| Ohio | 57 |
| Tennessee | 49 |
| Massachusetts | 43 |
| Michigan | 43 |
| Virginia | 43 |
| Colorado | 41 |
| Arizona | 36 |
Top cities
Houston, Texas 72New York, New York 55Los Angeles, California 45Pittsburgh, Pennsylvania 41Boston, Massachusetts 40Nashville, Tennessee 40San Francisco, California 30Dallas, Texas 29Columbus, Ohio 28Philadelphia, Pennsylvania 28
Self-screener
Recruiting trials
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
- A Clinical Study of T3011 in Subjects With Advanced Melanoma
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
- A Phase II Trial of LM103 in Advanced Melanoma
- A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
- A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
- A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
- A Study of BI 3810944 in Patients With Advanced Cancer
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
- A Study of DEG6498 in Participants With Solid Tumors
- A Study of DXC014 in Patients With Advanced Solid Tumors.
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- A Study of GC101 TIL in Advanced Melanoma
- A Study of GC101 TIL in Advanced Melanoma (10hospital)
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
- A Study of IBI363 in Subjects With Advanced Melanoma
- A Study of IBI363 in Subjects with Advanced Solid Malignancies
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- A Study of NX-1607 in Adults With Advanced Malignancies
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- A Study of ST-1898 for Unresectable or Metastatic Melanoma
- A Study of TRK-950 in Patients With Advanced Solid Tumors
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- ACTengine® IMA203 Combined With mRNA-4203
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- AI-Driven Early Detection of Skin Cancer
- AMT-253 in Patients With Advanced Solid Tumours
- APA (Adapted Physical Activity) for Patients With Advanced Melanoma
- Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
- Adjuvant Melatonin for Uveal Melanoma
- Adjuvant Quisinostat in High-Risk Uveal Melanoma
- Adjuvant Tebentafusp in High Risk Ocular Melanoma
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Related conditions
Trials recruiting for Melanoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Breast cancer 2239Colorectal cancer 1359Pancreatic cancer 870Non-small cell lung cancer 507Metastatic Melanoma 40Prostate cancer 1234Melanoma (Skin Cancer) 30Ovarian cancer 118Cutaneous Melanoma 27
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Melanoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.